Australia Stock Exchange release from NOXOPHARM : Pre-clinical Data Supports a Role for Veyonda in COVID-19
23/08/2021 01:00
Australia Stock Exchange release from NOXOPHARM NOX.AX : Pre-clinical Data Supports a Role for Veyonda in COVID-19
Recent news on Noxopharm
See all newsBrief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential
Brief: Noxopharm Says New Data Confirms Cancer-Fighting Potential
Brief: Noxopharm Appoints Dr Olivier Laczka As New CEO
Brief: Noxopharm Ltd Announces Resignation Of Chief Executive Officer